1. Launay, O. et al. Immunogenicity and safety of Beta-adjuvanted recombinant booster vaccine. N. Engl. J. Med. 387, 374–376 (2022).
2. Branche, A. R. et al. SARS-CoV-2 variant vaccine boosters trial: preliminary analyses. Preprint at https://www.medrxiv.org/content/10.1101/2022.07.12.22277336v1 (2022).
3. Chalkias, S. et al. Safety, immunogenicity and antibody persistence of a bivalent beta-containing booster vaccine. Nat. Med. 28, 2388–2397 (2022).
4. Chalkias, S. et al. A bivalent Omicron-containing booster vaccine against Covid-19. N. Engl. J. Med. 387, 1279–1291 (2022).
5. Moderna. Moderna’s omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrates significantly higher neutralizing antibody response against Omicron subvariants BA.4/5 compared To currently authorized booster. Moderna https://www.accesswire.com/708109/Modernas-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273214-Demonstrates-Significantly-Higher-Neutralizing-Antibody-Response-Against-Omicron-Subvariants-BA45-Compared-To-Currently-Authorized-Booster (2022).